Beyond Neoantigen Prediction: Using the Patient’s Own Tumour to Drive Personalised Cancer Vaccines

• Presenting CellVax’s Tumour Presenting Cell (TPC) platform, a personalised cancer vaccine approach that leverages the patient’s own tumour cells to present the full repertoire of tumour antigens without the need for neoantigen prediction algorithms
• Updating on the clinical and translational insights from the ongoing Phase 2 trial of FK-PC101 in high-risk prostate cancer patients following prostatectomy, including immune activation signals and long-term immunological responses
• Exploring how a tumour-derived antigen presentation may enable a simpler, faster, and potentially more scalable pathway for personalised cancer vaccines compared to sequencing-driven neoantigen approaches

Speakers:

Fernando Kreutz

Chief Executive Officer

Cellvax Therapeutics